Change in haemodynamics from baseline (the last documented value while still receiving phosphodiesterase-5 inhibitor) to week 24 and last-observation-carried-forward (LOCF) sensitivity analysis
| Parameter | N | Value at week 24 | Change from baseline to week 24# | n | LOCF | LOCF change from baseline |
| PVR dyn·s·cm–5 | 49 | 753±379 | –103±296 | 61 | 762±367 | –74±277 |
| Cardiac output L·min–1 | 49 | 4.7±1.2 | +0.6±0.9 | 61 | 4.6±1.1 | +0.4±0.9 |
| Cardiac index L·min–1·m–2 | 48 | 2.6±0.6 | +0.3±0.5 | 61 | 2.6±0.5 | +0.2±0.5 |
| mPAP mmHg | 49 | 50±13 | –2.8±8.8 | 61 | 50±14 | –2.2±8.0 |
| RAP mmHg | 49 | 8.0±4.3 | –0.8±4.2 | 61 | 7.7±4.4 | –0.6±3.8 |
| SvO2¶ % | 44 | 65.0±7.6 | +1.0±6.3 | 58 | 65.4±7.0 | +0.7±5.5 |
| SVR+ dyn·s·cm–5 | 49 | 1417±398 | –218±444 | 60 | 1446±388 | –179±415 |
| PAWP mmHg | 49 | 9.0±4.1 | –0.7±4.2 | 61 | 8.9±4.1 | –0.5±3.8 |
| SBP mmHg | 53 | 113±13 | –5±16 | 61 | 112±15 | –6±15 |
| DBP mmHg | 53 | 68±8 | –4±12 | 61 | 68±10 | –5±12 |
| Heart rate beats per min | 53 | 74±12 | <–0.5±11 | 61 | 77±12 | +2±11 |
Data are presented as mean±sd, unless otherwise stated. #: these data include only those patients for whom the respective variables were available at baseline and at week 24; ¶: data missing at baseline for two patients; +: data missing at baseline for one patient. PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; RAP: right atrial pressure; SvO2 : mixed venous oxygen saturation; SVR: systemic vascular resistance; PAWP: pulmonary artery wedge pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.